Dr lalchandani labs has received a disclosure from Anuraag Gambhir regarding substantial acquisition of shares under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The disclosure, dated March 05, 2026, reveals a significant increase in Gambhir's shareholding through a rights issue allotment.

Acquisition Details

Anuraag Gambhir acquired 13,00,000 equity shares through rights issue allotment completed on March 02, 2026. This acquisition represents a substantial 15.05% of the company's total voting capital, marking a significant investment in the pharmaceutical company.

Shareholding Pattern Changes

The acquisition resulted in a dramatic change in Gambhir's shareholding position. Prior to this transaction, he held a minimal stake of just 02 shares with negligible percentage holding.

Company Capital Structure Impact

The rights issue significantly expanded Dr. Lalchandani Labs Limited's equity base. The company's equity share capital increased substantially following the completion of the rights issue.

Regulatory Compliance

The disclosure was made in compliance with Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Gambhir confirmed that he does not belong to the promoter or promoter group category. The company's shares are listed on BSE Limited, and the disclosure has been filed with both the stock exchange and the company's board of directors.

This substantial acquisition represents one of the significant shareholding changes in Dr. Lalchandani Labs Limited, with Gambhir emerging as a notable shareholder through the rights issue participation.

Dr Lalchandani Labs has successfully completed its rights issue allotment, marking a significant milestone in the company's capital expansion strategy. The pathology laboratory company announced the allotment of 43,04,000 fully paid-up equity shares on March 02, 2026, effectively doubling its paid-up share capital through a formal disclosure to BSE Limited under SEBI Listing Regulations.

Rights Issue Structure and Timeline

The rights issue was initially disclosed on January 20, 2026, with the company proposing to raise ₹430.40 lakhs through the issuance of equity shares. The subscription period commenced on February 04, 2026, and concluded on February 27, 2026, providing eligible shareholders with the opportunity to subscribe to new shares at par value.

Share Capital Transformation

The allotment has resulted in a substantial increase in the company's equity base, with the paid-up share capital witnessing a complete doubling following the successful rights issue completion. The shares were allotted to eligible shareholders and renouncees as per the finalized basis of allotment.

Board Approval and Regulatory Process

The Board of Directors convened on March 02, 2026, from 07:00 PM to 07:55 PM to formalize the allotment decision. The approval process involved consultation with Cameo Corporate Services Limited, serving as the registrar to the issue, and received necessary approvals from BSE Limited as the designated stock exchange for the rights issue.

The allotment was conducted in accordance with the Letter of Offer dated January 20, 2026, ensuring compliance with SEBI Listing Regulations under Regulation 30. The formal disclosure was communicated to BSE Limited at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai, maintaining transparency with the stock exchange.

Corporate Governance and Disclosure

The disclosure demonstrates the company's commitment to transparency and regulatory compliance, with all relevant information made available on the company's website at lalchandanipathlab.com. The formal communication was digitally signed by Arjan Lalchandani, Managing Director (DIN: 07014579), ensuring proper corporate authorization for this significant capital market transaction.